It was shown that cancer progression [45] and different chemotherapies [53] have strong impacts on NK cell functionality and hence, might interfere with the simple assessment of FcγRIIIa-V158F polymorphisms to predict mAb-induced ADCC in vivo. This evidence concerns the gene FCGR3A and cancer.